Skip to main content

Table 3 Internal validation of the estrogen receptor (ER)-specific risk prediction models (ModelFR+ and ModelFR-) by fivefold cross-validation, overall and by age, in the women from the European Prospective Investigation into Cancer and Nutrition (EPIC) study

From: Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

  ModelER+ ModelER- Omnibus model
C-statistic (95% CI)
 Before eliminating country effect 0.68 (0.65–0.70) 0.68 (0.64–0.72) 0.68 (0.66–0.70)
 After eliminating country effect
  Overall 0.64 (0.61–0.67) 0.59 (0.54–0.64) 0.63 (0.60–0.65)
  By menopausal status
   Premenopausal 0.64 (0.59–0.68) 0.58 (0.51–0.66) 0.62 (0.59–0.66)
   Postmenopausal 0.62 (0.59–0.66) 0.60 (0.52–0.67) 0.62 (0.59–0.65)
  By ER status
   ER+ 0.64 (0.62–0.67)
   ER− 0.59 (0.53–0.64)
Ratio of observed–expected (95% CI)
 Overall 1.10 (1.05–1.14) 0.96 (0.88–1.05) 1.07 (1.03–1.11)
 By menopausal status
  Premenopausal 1.13 (1.06–1.20) 0.97 (0.85–1.10) 1.09 (1.02–1.15)
  Postmenopausal 1.07 (1.02–1.13) 0.96 (0.84–1.08) 1.06 (1.00–1.11)